Thermo Fisher Scientific (TMO) Non-Current Deferred Tax Liability (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported Non-Current Deferred Tax Liability for 18 consecutive years, with $1.6 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Deferred Tax Liability rose 153.04% year-over-year to $1.6 billion; the trailing twelve-month figure through Jun 2026 stood at $1.6 billion (up 153.04% YoY), and the FY2025 full-year result was $1.5 billion, up 17.74% from the prior year.
• Non-Current Deferred Tax Liability declined to $1.6 billion in Q2 2026 per TMO's latest filing, from $2.1 billion in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $3.5 billion in Q2 2022 and bottomed at $624.0 million in Q2 2025.
• Historically, Non-Current Deferred Tax Liability has averaged $2.0 billion across 5 years, with a median of $1.9 billion in 2023.
• The sharpest annual moves came in 2025 and 2026: Non-Current Deferred Tax Liability slumped 58.84% in 2025, then jumped 153.04% in 2026.
• Over 5 years, Non-Current Deferred Tax Liability stood at $2.8 billion in 2022, then sank by 32.54% to $1.9 billion in 2023, then tumbled by 34.03% to $1.3 billion in 2024, then advanced by 17.74% to $1.5 billion in 2025, then rose by 5.76% to $1.6 billion in 2026.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $1.6 billion, $2.1 billion, and $1.5 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.